v3.25.1
Pay vs Performance Disclosure - USD ($)
 1 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 14, 2020
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure              
Pay vs Performance Disclosure, Table    

PAY VERSUS PERFORMANCE

The following tables and related disclosures provide information about (i) the total compensation of our principal executive officers, or our PEOs, and our other named executive officers, or our Other NEOs, as presented in the Summary Compensation Tables for the applicable years, or the SCT Amounts; (ii) the compensation actually paid to our PEOs and our Other NEOs, as calculated pursuant to the SEC’s pay-versus-performance rules, or the CAP Amounts; (iii) certain financial performance measures; and (iv) the relationship of the CAP Amounts to those financial performance measures.

This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K under the Exchange Act and Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and does not necessarily reflect value actually realized by our executive officers or how our Compensation Committee evaluates compensation decisions in light of company or individual performance. SEC rules require certain adjustments be made to the SCT Amounts to determine compensation actually paid as reported in the Pay Versus Performance Table below. In general, compensation actually paid is calculated by adjusting the SCT Amounts to include the fair market value of equity awards as of December 31 of the applicable year or, if earlier, the vesting date (rather than the grant date). The Company does not have a defined benefit plan so no adjustment for pension benefits is included in the table. Similarly, no adjustment is made for dividends as the Company does not pay dividends. For discussion of how our Compensation Committee seeks to align pay with performance when making compensation decisions, please review Compensation Discussion and Analysis beginning on page 48.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Value of Initial Fixed $100
Investment Based On:

 

 

 

 

 

 

Fiscal Year

 

Summary
Compensation
Table Total
for First PEO
(6)($)

 

 

Summary
Compensation
Table Total
for Second PEO
(6)($)

 

 

Compensation
Actually Paid
to First PEO
(7)($)

 

 

Compensation
Actually Paid
to Second PEO
(7)($)

 

 

Average
Summary
Compensation
Table Total
for Non-PEO
NEOs(6)($)

 

 

Average
Compensation
Actually Paid
to Non-PEO
NEOs(7)($)

 

 

Total
Shareholder
Return(8)

 

 

Peer
Group
Total
Shareholder
Return(9)

 

 

Net
income
(loss)
($ millions)(10)

 

 

Company
Selected
Measure(11)

2024(1)

 

 

7,112,589

 

 

 

—

 

 

 

864,959

 

 

 

—

 

 

 

2,325,419

 

 

 

762,383

 

 

$

8

 

 

$

114

 

 

 

(400.7

)

 

N/A

2023(2)

 

 

6,237,491

 

 

 

—

 

 

 

3,080,628

 

 

 

—

 

 

 

2,312,755

 

 

 

200,268

 

 

$

30

 

 

$

115

 

 

 

(541.5

)

 

N/A

2022(3)

 

 

5,705,164

 

 

 

—

 

 

 

3,563,623

 

 

 

—

 

 

 

2,282,416

 

 

 

2,071,551

 

 

$

53

 

 

$

111

 

 

 

(532.8

)

 

N/A

2021(4)

 

 

58,864,150

 

 

 

—

 

 

 

8,431,100

 

 

 

—

 

 

 

3,024,803

 

 

 

534,653

 

 

$

59

 

 

$

125

 

 

 

(457.9

)

 

N/A

2020(5)

 

 

826,052

 

 

 

4,670,003

 

 

 

1,265,945

 

 

 

4,698,361

 

 

 

2,718,961

 

 

 

3,077,346

 

 

$

120

 

 

$

126

 

 

 

606.1

 

 

N/A

 

(1)
For 2024, our PEO was Barry E. Greene and our Other NEOs were Christopher Benecchi, Gregory Shiferman, Laura Gault, M.D., Ph.D., Kimi Iguchi, and Anne Marie Cook.
(2)
For 2023, our PEO was Barry E. Greene and our Other NEOs were Kimi Iguchi, Christopher Benecchi, Anne Marie Cook, Laura Gault, M.D., Ph.D., and Albert Robichaud, Ph.D.
(3)
For 2022, our PEO was Barry E. Greene and our Other NEOs were Kimi Iguchi, Christopher Benecchi, Anne Marie Cook and Laura Gault, M.D., Ph.D.
(4)
For 2021, our PEO was Barry E. Greene and our Other NEOs were Kimi Iguchi, Christopher Benecchi, Jeffrey M. Jonas, M.D. and Albert Robichaud, Ph.D.
(5)
For 2020, Barry E. Greene was our PEO from December 15, 2020 through December 31, 2020 and is referred to as the First PEO. Jeffrey M. Jonas, M.D. was our PEO from January 1, 2020 through December 14, 2020 and is referred to as the Second PEO. Our Other NEOs were Kimi Iguchi, Michael Cloonan, Anne Marie Cook and Albert Robichaud, Ph.D.
(6)
For the years 2024, 2023, 2022, 2021 and 2020, these SCT Amounts are total compensation, as shown in the Summary Compensation Table from the relevant year.
(7)
The SCT Amounts reported for our PEO or PEOs, as applicable, and the average of our Other NEOs for each year were subject to the following adjustments per Item 402(v)(2)(iii) of Regulation S-K to calculate compensation actually paid:

First PEO – Barry E. Greene

 

Year

 

2020

 

 

2021

 

 

2022

 

 

2023

 

 

2024

 

SCT Amount

 

$

826,052

 

 

$

58,864,150

 

 

$

5,705,164

 

 

$

6,237,491

 

 

$

7,112,589

 

- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year

 

 

(771,858

)

 

 

(57,615,277

)

 

 

(4,413,009

)

 

 

(4,994,865

)

 

 

(5,833,627

)

+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year

 

 

1,157,954

 

 

 

6,065,298

 

 

 

3,806,807

 

 

 

1,060,858

 

 

 

569,251

 

+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years

 

 

—

 

 

 

(473,055

)

 

 

(1,068,567

)

 

 

(3,187,101

)

 

 

(695,484

)

+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year

 

 

53,797

 

 

 

1,728,189

 

 

 

—

 

 

 

—

 

 

 

451,584

 

+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year

 

 

—

 

 

 

(138,205

)

 

 

(466,772

)

 

 

3,964,245

 

 

 

(739,354

)

- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

CAP Amount

 

$

1,265,945

 

 

$

8,431,100

 

 

$

3,563,623

 

 

$

3,080,628

 

 

$

864,959

 

 

Second PEO – Jeffrey M. Jonas, M.D.

 

Year

 

2020

 

 

2021

 

 

2022

 

 

2023

 

 

2024

 

SCT Amount

 

$

4,670,003

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year

 

 

(3,473,072

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year

 

 

3,922,803

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years

 

 

218,141

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year

 

 

(639,514

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

CAP Amount

 

$

4,698,361

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

 

Average – Non-PEO NEOs

 

Year

 

2020

 

 

2021

 

 

2022

 

 

2023

 

 

2024

 

SCT Amount

 

$

2,718,961

 

 

$

3,024,803

 

 

$

2,282,416

 

 

$

2,312,755

 

 

$

2,325,419

 

- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year

 

 

(2,021,218

)

 

 

(2,376,000

)

 

 

(1,678,713

)

 

 

(1,475,326

)

 

 

(1,446,691

)

+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year

 

 

2,625,972

 

 

 

700,815

 

 

 

1,620,274

 

 

 

266,964

 

 

 

133,580

 

+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years

 

 

114,460

 

 

 

(936,801

)

 

 

(81,245

)

 

 

(1,067,772

)

 

 

(206,237

)

+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

113,438

 

+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year

 

 

(360,829

)

 

 

121,836

 

 

 

(71,181

)

 

 

163,647

 

 

 

(73,968

)

- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(83,158

)

CAP Amount

 

$

3,077,346

 

 

$

534,653

 

 

$

2,071,551

 

 

$

200,268

 

 

$

762,383

 

 

(8)
Sage TSR for the common stock of the Company assumes the investment of $100 in our common stock on the last trading day before the earliest fiscal year in the above table through and including the end of the fiscal year for which TSR is shown.
(9)
The Peer Group TSR is the total stockholder return for the Nasdaq Biotechnology Index.
(10)
The net income shown for the fiscal year 2020 includes an up-front amount and payment for shares of our common stock received from Biogen in connection with the effectiveness of the Biogen Collaboration and License Agreement (as defined in the section entitled “Certain Relationships and Related Party Transactions” below).
(11)
The following table lists the four categories of non-financial performance measures that, in our assessment, represent the most important performance measures we use to link the CAP Amounts for our PEO and Other NEOs for 2024 (our most recently completed fiscal year) to company performance. While we utilize these and other performance-based measures to align our executive officer compensation with our performance and potential value creation for our stockholders, including in connection with their annual bonus opportunity and in setting performance-based milestones for PSUs, as more fully described in Compensation Discussion and Analysis in this Proxy Statement, we do not currently use financial performance measures in setting compensation for our executive officers, and accordingly, a company-selected measure based on financial performance is not included in the pay versus performance table above.
        
Named Executive Officers, Footnote    
(1)
For 2024, our PEO was Barry E. Greene and our Other NEOs were Christopher Benecchi, Gregory Shiferman, Laura Gault, M.D., Ph.D., Kimi Iguchi, and Anne Marie Cook.
(2)
For 2023, our PEO was Barry E. Greene and our Other NEOs were Kimi Iguchi, Christopher Benecchi, Anne Marie Cook, Laura Gault, M.D., Ph.D., and Albert Robichaud, Ph.D.
(3)
For 2022, our PEO was Barry E. Greene and our Other NEOs were Kimi Iguchi, Christopher Benecchi, Anne Marie Cook and Laura Gault, M.D., Ph.D.
(4)
For 2021, our PEO was Barry E. Greene and our Other NEOs were Kimi Iguchi, Christopher Benecchi, Jeffrey M. Jonas, M.D. and Albert Robichaud, Ph.D.
(5)
For 2020, Barry E. Greene was our PEO from December 15, 2020 through December 31, 2020 and is referred to as the First PEO. Jeffrey M. Jonas, M.D. was our PEO from January 1, 2020 through December 14, 2020 and is referred to as the Second PEO. Our Other NEOs were Kimi Iguchi, Michael Cloonan, Anne Marie Cook and Albert Robichaud, Ph.D.
        
Peer Group Issuers, Footnote    
(9)
The Peer Group TSR is the total stockholder return for the Nasdaq Biotechnology Index.
        
Adjustment To PEO Compensation, Footnote    

First PEO – Barry E. Greene

 

Year

 

2020

 

 

2021

 

 

2022

 

 

2023

 

 

2024

 

SCT Amount

 

$

826,052

 

 

$

58,864,150

 

 

$

5,705,164

 

 

$

6,237,491

 

 

$

7,112,589

 

- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year

 

 

(771,858

)

 

 

(57,615,277

)

 

 

(4,413,009

)

 

 

(4,994,865

)

 

 

(5,833,627

)

+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year

 

 

1,157,954

 

 

 

6,065,298

 

 

 

3,806,807

 

 

 

1,060,858

 

 

 

569,251

 

+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years

 

 

—

 

 

 

(473,055

)

 

 

(1,068,567

)

 

 

(3,187,101

)

 

 

(695,484

)

+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year

 

 

53,797

 

 

 

1,728,189

 

 

 

—

 

 

 

—

 

 

 

451,584

 

+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year

 

 

—

 

 

 

(138,205

)

 

 

(466,772

)

 

 

3,964,245

 

 

 

(739,354

)

- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

CAP Amount

 

$

1,265,945

 

 

$

8,431,100

 

 

$

3,563,623

 

 

$

3,080,628

 

 

$

864,959

 

 

Second PEO – Jeffrey M. Jonas, M.D.

 

Year

 

2020

 

 

2021

 

 

2022

 

 

2023

 

 

2024

 

SCT Amount

 

$

4,670,003

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year

 

 

(3,473,072

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year

 

 

3,922,803

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years

 

 

218,141

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year

 

 

(639,514

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

CAP Amount

 

$

4,698,361

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 
       
Non-PEO NEO Average Total Compensation Amount     $ 2,325,419 $ 2,312,755 $ 2,282,416 $ 3,024,803 $ 2,718,961
Non-PEO NEO Average Compensation Actually Paid Amount     $ 762,383 200,268 2,071,551 534,653 3,077,346
Adjustment to Non-PEO NEO Compensation Footnote    

Average – Non-PEO NEOs

 

Year

 

2020

 

 

2021

 

 

2022

 

 

2023

 

 

2024

 

SCT Amount

 

$

2,718,961

 

 

$

3,024,803

 

 

$

2,282,416

 

 

$

2,312,755

 

 

$

2,325,419

 

- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year

 

 

(2,021,218

)

 

 

(2,376,000

)

 

 

(1,678,713

)

 

 

(1,475,326

)

 

 

(1,446,691

)

+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year

 

 

2,625,972

 

 

 

700,815

 

 

 

1,620,274

 

 

 

266,964

 

 

 

133,580

 

+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years

 

 

114,460

 

 

 

(936,801

)

 

 

(81,245

)

 

 

(1,067,772

)

 

 

(206,237

)

+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

113,438

 

+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year

 

 

(360,829

)

 

 

121,836

 

 

 

(71,181

)

 

 

163,647

 

 

 

(73,968

)

- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(83,158

)

CAP Amount

 

$

3,077,346

 

 

$

534,653

 

 

$

2,071,551

 

 

$

200,268

 

 

$

762,383

 
       
Compensation Actually Paid vs. Total Shareholder Return    

The following chart depicts the relationship of CAP Amounts for our PEOs and Other NEOs as compared to the cumulative TSR of our common stock and the Peer Group TSR, as well as the relationship between our TSR and the Peer Group TSR, over the past five years.

 

img95046853_8.jpg

        
Compensation Actually Paid vs. Net Income    

The following chart depicts the relationship of CAP Amounts for our PEOs and Other NEOs as compared to net income over the past five years. The net income shown for the fiscal year 2020 includes an up-front amount and payment for shares of our common stock received from Biogen in connection with the effectiveness of the Biogen Collaboration and License Agreement (as defined in the section entitled “Certain Relationships and Related Party Transactions” below).

 

img95046853_9.jpg

        
Total Shareholder Return Vs Peer Group    

The following chart depicts the relationship of CAP Amounts for our PEOs and Other NEOs as compared to the cumulative TSR of our common stock and the Peer Group TSR, as well as the relationship between our TSR and the Peer Group TSR, over the past five years.

 

img95046853_8.jpg

        
Tabular List, Table    
(11)
The following table lists the four categories of non-financial performance measures that, in our assessment, represent the most important performance measures we use to link the CAP Amounts for our PEO and Other NEOs for 2024 (our most recently completed fiscal year) to company performance. While we utilize these and other performance-based measures to align our executive officer compensation with our performance and potential value creation for our stockholders, including in connection with their annual bonus opportunity and in setting performance-based milestones for PSUs, as more fully described in Compensation Discussion and Analysis in this Proxy Statement, we do not currently use financial performance measures in setting compensation for our executive officers, and accordingly, a company-selected measure based on financial performance is not included in the pay versus performance table above.

 

Strategic Regulatory Milestones

Pre-Launch and Launch Readiness Goals

Research and Development Pipeline Goals

Hiring and Workforce Development Goals
       
Total Shareholder Return Amount     $ 8 30 53 59 120
Peer Group Total Shareholder Return Amount     114 115 111 125 126
Net Income (Loss)     $ (400,700,000) (541,500,000) (532,800,000) (457,900,000) 606,100,000
Measure:: 1              
Pay vs Performance Disclosure              
Name     Strategic Regulatory Milestones        
Measure:: 2              
Pay vs Performance Disclosure              
Name     Pre-Launch and Launch Readiness Goals        
Measure:: 3              
Pay vs Performance Disclosure              
Name     Research and Development Pipeline Goals        
Measure:: 4              
Pay vs Performance Disclosure              
Name     Hiring and Workforce Development Goals        
Barry E. Greene [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount     $ 7,112,589 6,237,491 5,705,164 58,864,150 826,052
PEO Actually Paid Compensation Amount     $ 864,959 $ 3,080,628 $ 3,563,623 $ 8,431,100 1,265,945
PEO Name Barry E. Greene   Barry E. Greene Barry E. Greene Barry E. Greene Barry E. Greene  
Jeffrey M. Jonas, M.D [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount             4,670,003
PEO Actually Paid Compensation Amount             4,698,361
PEO Name   Jeffrey M. Jonas, M.D.          
PEO | Barry E. Greene [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     $ (5,833,627) $ (4,994,865) $ (4,413,009) $ (57,615,277) (771,858)
PEO | Barry E. Greene [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     569,251 1,060,858 3,806,807 6,065,298 1,157,954
PEO | Barry E. Greene [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (695,484) (3,187,101) (1,068,567) (473,055)  
PEO | Barry E. Greene [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     451,584     1,728,189 53,797
PEO | Barry E. Greene [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (739,354) 3,964,245 (466,772) (138,205)  
PEO | Jeffrey M. Jonas, M.D [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount             (3,473,072)
PEO | Jeffrey M. Jonas, M.D [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount             3,922,803
PEO | Jeffrey M. Jonas, M.D [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount             218,141
PEO | Jeffrey M. Jonas, M.D [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount             (639,514)
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (1,446,691) (1,475,326) (1,678,713) (2,376,000) (2,021,218)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     133,580 266,964 1,620,274 700,815 2,625,972
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (206,237) (1,067,772) (81,245) (936,801) 114,460
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     113,438        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (73,968) $ 163,647 $ (71,181) $ 121,836 $ (360,829)
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     $ (83,158)